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ARTICLE
Modeling germline mutations in pineoblastoma
uncovers lysosome disruption-based therapy
Philip E. D. Chung1,2, Deena M. A. Gendoo3,15, Ronak Ghanbari-Azarnier1,2,15, Jeff C. Liu1, Zhe Jiang1,
Jennifer Tsui1, Dong-Yu Wang 1, Xiao Xiao1,4,5, Bryan Li 2,5, Adrian Dubuc2,6, David Shih 2,6, Marc Remke6,
Ben Ho6, Livia Garzia6,7, Yaacov Ben-David4,5, Seok-Gu Kang 8, Sidney Croul9, Benjamin Haibe-Kains10,11,12,
Annie Huang2,5, Michael D. Taylor 2,5,13 & Eldad Zacksenhaus1,2,14✉
Pineoblastoma is a rare pediatric cancer induced by germline mutations in the tumor sup-
pressors RB1 or DICER1. Presence of leptomeningeal metastases is indicative of poor prog-
nosis. Here we report that inactivation of Rb plus p53 via a WAP-Cre transgene, commonly
used to target the mammary gland during pregnancy, induces metastatic pineoblastoma
resembling the human disease with 100% penetrance. A stabilizing mutation rather than
deletion of p53 accelerates metastatic dissemination. Deletion of Dicer1 plus p53 via WAP-
Cre also predisposes to pineoblastoma, albeit with lower penetrance. In silico analysis
predicts tricyclic antidepressants such as nortriptyline as potential therapeutics for both
pineoblastoma models. Nortriptyline disrupts the lysosome, leading to accumulation of non-
functional autophagosome, cathepsin B release and pineoblastoma cell death. Nortriptyline
further synergizes with the antineoplastic drug gemcitabine to effectively suppress pine-
oblastoma in our preclinical models, offering new modality for this lethal childhood
malignancy.
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P ineoblastoma (PB) is a rare but aggressive tumor of thepineal gland1–4. It affects approximately equally males andfemales with overall survival (OS) rate of about 54%. Sur-
vival drops to 15% in children ≤5 years of age3, and the presence
of metastases at diagnosis is indicative of exceedingly poor clinical
outcome4. While PB affects adults, most cases occur in young
children with a median latency of ~5–6 years. Early symptoms
include headache, ocular disturbance, ataxia and increased
intracranial pressure due to hydrocephalus. Current treatments
comprise maximal tumor resection followed by radiation and
chemotherapy.
About 5% of patients with bilateral retinoblastoma (RB), an
ocular tumor of infancy, develop PB, termed “trilateral RB”,
directly implicating the tumor suppressor RB1 in the aetiology of
this disease5. Although new chemotherapy regimens have
improved outcome, 5-year OS of trilateral RB patients is only
44%, with the presence of leptomeningeal metastases associated
with reduced survival5. Germline mutation in DICER1 also pre-
disposes to PB6–8, whereas DROSHA loss and PDE4DIP dupli-
cation are found in sporadic cases9. Recent molecular
classification of PBs identified several subtypes with distinct
oncogenic alterations and clinical/pathological features. RB1 loss
or amplification of MYC or the miR17-92 cluster is observed in
young children (median 1.3-1.4 years) with 5 year OS in this
cohort of 28.6% and 37.5%, respectively; whereas loss-of-function
alterations in genes involved in miRNA biogenesis (DICER1,
DROSHA, and DGCR8) characterize older patients (median age
5.2–14.0 years) with five-year OS of 68–100%10.
Rb+/−:p53−/− mice develop diverge tumor types including
pituitary, thyroid, lymphoma, sarcoma, islet cell, bronchial
hyperplasia, retinal dysplasia, and PB11. A major hurdle in
developing a specific model for PB has been the lack of a proper
CRE deleter line. An interphotoreceptor retinoid binding protein
promoter Cre transgenic line (IRBP-Cre) targets the pineal gland,
but also other lineages. Indeed, IRBP-Cre mediated deletion of Rb
on a p53+/− background led to anterior lobe tumors, pituitary
tumors, other tumors or no lesions at all in some mice as well as
PB in 15% of mice12. Here we have made the fortuitous discovery
that the whey acidic protein (WAP) promoter Cre deleter line
(WAP-Cre)13, commonly used to target mammary lobuloalveolar
progenitors during the estrous cycle and pregnancy, is expressed
in the pineal gland in both male and female mice, and that WAP-
Cre:Rbflox/flox:p53flox/flox and WAP-Cre:Rbflox/flox:p53lsl_R270H/flox
mice develop metastatic PBs that resemble the human disease
with short latency and 100% penetrance. Disruption of Dicer1
plus p53 also induces PB, though with longer latency and reduced
penetrance as observed in children. These results demonstrate the
utility of the WAP-Cre transgene for modeling diverse types of
PBs, and suggesting similar cell of origin for RB1- and DICER1-
deficient PB. In silico analysis predicts high sensitivity of mouse
PBs to FDA-approved tricyclic antidepressant drugs such as
nortriptyline (NOR). NOR disrupts the lysosome, leading to
inhibition of autophagic flux, cathepsin release and the demise of
both mouse and human PB cells. NOR further synergizes with the
antineoplastic drug gemcitabine to effectively suppress PB in vivo.
Thus, our results model the two most common germline muta-
tions, RB1 and DICER1, that predispose children to PB, and
uncover a new therapeutic avenue for this devastating disease.
Results
Rb plus p53 deletion via WAP-Cre induces metastatic PB. In
the course of studying the effect of deleting Rb in the mammary
epithelium via WAP-Cre14, we observed that WAP-Cre:Rbflox/
flox:p53flox/flox mice developed brain tumors with latency of
133 days and 100% penetrance (Fig. 1a). The tumors protruded
the head, and upon histological examination, were found to
engulf the entire superior part of the brain, invading the cere-
bellum (Fig. 1b, c). These lesions were observed in WAP-Cre:
Rbflox/flox:p53flox/flox (henceforth referred to as Rb/p53-deleted)
mice and in one of sixteen WAP-Cre:Rbflox/flox:p53flox/wt mice,
but not in WAP-Cre:Rbflox/flox, WAP-Cre:p53flox/flox, or WAP-
Cre:Rbflox/flox:Ptenflox/flox mice15 (Fig. 1a). Human PBs display
Homer Wright and Flexner-Wintersteiner rosettes16,17, irregular,
pleomorphic nuclei, and scant cytoplasm18. The Rb/p53-deleted
PB exhibited similar histology with pleomorphic nuclei, scarce
cytoplasm and rosette features (Fig. 1d). Deletion of the floxed Rb
and p53 alleles, and loss of protein expression in these tumors
were confirmed (Fig. 1e).
To determine the origin of these tumors, we monitored their
development by magnetic resonance imaging (MRI). While
human pineal gland is located in the posterior segment of the
diencephalon at the center of the brain, mouse pineal gland is
positioned on the dorsal part of the brain between the midbrain
and the cerebral cortex19. MRI of a 50-day-old mouse identified a
small lesion on the superior side of the midbrain, which became
larger in subsequent imaging at 70 and 106 days of age in
the same mouse (Fig. 1f). To further pinpoint the tissue of origin,
we crossed WAP-Cre:Rbflox/flox:p53flox/flox mice to mT/mG
double fluorescent Cre reporter line in which all cells fluoresce
tomato-red unless the mT cassette is deleted via Cre-mediated
recombination, inducing expression of enhanced Green Fluor-
escent Protein (eGFP)20. WAP-Cre:Rbflox/flox:p53flox/flox:mT/mG
mice exhibited large green-fluorescent tumors on a red-
fluorescent background (Fig. 1g). Imaging of pineal glands from
young mice uncovered “green” micro-tumors at as early as
18 days of age; these micro-lesions were observed in H&E stained
sections and by ki67 staining, revealing highly proliferative tumor
cells with similar histology as full-blown PB (Fig. 1h, Supple-
mentary Fig. 1a). Notably, the WAP-Cre transgene was reported
to be expressed in the brain13. However, endogenous WAP gene
is expressed at background levels in the pineal gland (Supple-
mentary Fig. 2), suggesting that expression of the WAP-Cre
transgene in this gland is likely the result of ectopic activation at
the integration site.
Human PBs express neuronal markers such as synaptophysin,
but little or no expression of glial markers like glial fibrillary
acidic protein (GFAP)18. In accordance Rb/p53-deleted PBs
showed widespread expression of synaptophysin but not GFAP or
the epithelial markers pan cytokeratin (PanCK) and epithelial
membrane antigen (EMA; Fig. 1i). Like human PBs, which
exhibit a proliferation index of over 36%21, Rb/p53-deleted PBs
were highly proliferative as shown by strong and widespread ki67
expression (Fig. 1j). Consistent with p53 deletion, these tumors
stained negative for p53 (Fig. 1k). Occasionally, Rb/p53-deleted
mice developed pituitary tumors, which were observed as small
lesions in mice with end stage PB (Supplementary Fig. 1b).
Metastasis is a poor prognostic marker for PB4. Analysis of
whole brains and spinal cords from WAP-Cre:Rbflox/flox:p53flox/
flox:mT/mG mice revealed multiple large metastatic lesions on the
leptomeningeal surface of the spine (Fig. 1l). Thus, combined
deletion of Rb plus p53 via WAP-Cre induces metastatic PB with
100% penetrance and features of human PB.
Cluster analysis of Rb/p53-deficient PB. We next classified the
mouse Rb/p53-deficient PBs using whole genome mRNA gene-
set enrichment analysis (GSEA)-based principle component
analysis (PCA)22 of 12 Rb/p53-deleted PB samples in comparison
to human PB, Group 3, Group 4, and SHH medulloblastoma
(MB), RB, and glioblastoma (GBM) as well as mouse RB. The Rb/
p53-deleted PBs clustered close to mouse RB and human PB as
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well as to Group 3 and Group 4 MBs, but relatively far from GBM
as recently established for human brain tumors23,24 (Fig. 2a,
Supplementary Fig. 3).
Like group 3 MB, which expresses photoreceptor genes25,
mouse PBs exhibited high levels of Tulp1, Impg2, and Ush2a
relative to SHHMBs (Fig. 2b). We directly compared mouse PB to
human MB using a 75-gene classifier (Fig. 2b and Supplementary
Table 1)26. Mouse Rb/p53-deleted PBs resembled Group 3 MB
with low expression of Atoh1, Boc, Hhip, Cxcr4 and Sfrp1, and
high levels of Impg2, Rasgrf2, Ush2a, Cadm2, and Tulp1 (Fig. 2b).
We then compared expression profiles of these 10 genes in
human PBs versus human SHH and group 3 MBs in an
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independent dataset27; human PBs exhibited expression profiles
similar to group 3 MB but not SHH MB (Fig. 2c). Thus, Rb/p53-
deleted PBs are similar to both human PB and group 3 MB.
Next, we developed a 95-gene classifier that can differentiate
human PB from human SHH MB (Fig. 2d; Supplementary
Table 1). Using this classifier, Rb/p53-deleted PBs were again
highly similar to human PB (Fig. 2d). Overall, these results
indicate that mouse Rb/p53-deleted PB highly resembles human
PB, and thus, WAP-Cre:Rbflox/flox:p53flox/flox mice may serve as a
preclinical model for this deadly disease.
Rb/p53-R270H PB exhibits enhanced metastasis. In human
cancer, p53 disruption involves large deletions of the gene or
mutations that usually affect the DNA-binding domain, creating
dominant-negative or gain of function alleles28. Although the
status of p53 in human PB is not fully established, progression to
full-blown PB is associated with high p53 immuno-staining,
suggesting stabilizing p53 mutation29. We therefore determined
the effect of expressing a p53 mutant allele, R270H, with muta-
tion in the DNA-binding domain, on PB formation and dis-
semination28. WAP-Cre:Rbflox/flox:p53lsl_R270H/flox mice (n= 19;
henceforth referred to as Rb/p53-mutated) developed PB with
similar latency, penetrance, and histology compared with Rb/p53-
deleted PB and closely clustered with mouse Rb/p53-deleted and
human PB by GSEA-PCA (Fig. 2a; 3a–b). Tumor penetrance
decreased to 4/36 in WAP-Cre:Rbflox/flox:p53lsl_R270H/+ mice in
which the other chromosome retained a wild-type p53 allele
(Fig. 3a). Like Rb/p53-deleted lesions, Rb/p53-mutated PBs
stained positive for synaptophysin but not GFAP (Fig. 3c, d), and
in accordance with the R270H mutation, which stabilizes the
protein, stained strongly for p53 (Fig. 3e).
To identify differences between these two closely related
tumors, we performed GSEA30 combined with Enrichment Map
analysis31,32. Multiple immune response-related and metabolic
pathways were enriched in Rb/p53-deleted relative to Rb/p53-
mutated PBs, whereas cell cycle, mitotic replication, transcription,
mRNA processing, and Bard1 (BRCA1-associated RING domain
protein 1) pathways were enriched in Rb/p53-mutated compared
with Rb/p53-deleted PBs (Supplementary Fig. 4a). In addition,
four pathways involved in metastasis were enriched in the Rb/
p53-mutated vs Rb/p53-deleted PBs (Fig. 3f and Supplementary
Fig. 4b). In accordance, WAP-Cre:Rbflox/flox:p53lsl_R270H/flox mice
exhibited not only metastases to the leptomeningeal surface of the
spinal cord as seen in Rb/p53-deleted mice but also to
leptomeningeal surfaces in the brain (Fig. 3g). Furthermore, Rb/
p53-mutated PBs showed significantly more metastasis (60%)
compared to Rb/p53-deleted (22%) (P < 0.0001; Fig. 3g), indicating
that the p53-R270H allele exerts a gain-of-function effect in this
context.
NOR predicted as therapeutic drug for PB. Although new
chemotherapy regimens have improved 5-year OS of PB patients,
survival rates drop to 15% in ≤5-year-old patients, and tumors
that shed metastases are virtually incurable3. There is therefore a
pressing need to develop new approaches to treat metastatic PB.
We used mRNA expression data from the two mouse PB models
to calculate connectivity scores33 using GSEA and genome-wide
connectivity (GWC) mapping34,35. This in silico analysis con-
sistently identified tricyclic drugs, some of which are FDA-
approved antidepressants or antipsychotics, including NOR,
promazine, norcyclobenzaprine and amitriptyline, as potential
inhibitors for both Rb/p53-deleted and Rb/p53-mutated PBs
(Fig. 4a; Supplementary Tables 2 and 3).
To investigate the effect of these antidepressant drugs, we
established primary Rb/p53-deleted PB cells, cultured in serum-
free media supplemented with EGF and FGF (Fig. 4b). Primary
PB cells expressed synaptophysin, and sprouted secondary
tumors following subcutaneous (sub. cu.) injection of 5 × 105
cells into immuno-deficient NOD/SCID mice (Fig. 4b). Second-
ary tumors were histologically similar to the primary PB with
pleomorphic nuclei and scant cytoplasm, though rosettes were
less obvious. Three independent primary PB cell lines (PB-1638,
PB-1979, PB-2804) as well as human group 3 MB cell line,
D425wt, showed significantly higher sensitivity to NOR, the top-
ranked antidepressant drug, compared to immortalized HaCaT
keratinocyte cells used as normal-like control (Fig. 4c).
NOR was shown to induce apoptosis in mouse bladder cancer
cells at concentrations of ≥25 µM36. To determine whether NOR
induced apoptosis in PB, cells were treated with NOR and tested
for caspase-3/caspase-7 activation. NOR had no significant effect
on caspase-3/7 activity after 1–2-h treatment, and only low
induction of these caspases after 24 h (Fig. 4d, left; Supplementary
Fig. 5a). In contrast, the anti-neoplastic cytotoxic drug gemcita-
bine, a nucleoside analog that interferes with DNA synthesis,
induced robust caspase-3/7 activity (Fig. 4d, right, Supplementary
Fig. 5a). Thus, short-term NOR treatment induces primarily a
non-apoptotic cell death in PB cells.
To ask whether NOR mono-therapy could attenuate PB
in vivo, we used MRI to monitor tumor growth. 70–80 day old
WAP-Cre:Rbflox/flox:p53flox/flox mice were treated with vehicle
alone or NOR (20 mg/kg, with gradual increase to 30 mg/kg and
then 40mg/kg, 5 days/week) for 5 weeks. MRI was performed just
prior to and at the end of drug treatment, and tumor volume was
computed by analyzing serial images (Supplementary Fig. 5b). On
Fig. 1 Deletion of Rb plus p53 via WAP-Cre induces pineoblastoma. a Kaplan–Meier pineoblastoma (PB)-free survival curves for the indicated mouse
models. WAP-Cre:Rbflox/flox:p53flox/flox mice (n= 149, red) developed PB with 100% penetrance and median latency of 133 days. One WAP-Cre:Rbflox/flox:
p53flox/+ mouse (n= 16, green) but none of WAP-Cre:Rbflox/flox (n= 56, black) or WAP-Cre:p53flox/flox (n= 41, black) mice developed PB. Statistical
analysis by Mantel-Cox test. b Appearance of a normal control versus a WAP-Cre:Rbflox/flox:p53flox/flox mouse with a bulging PB. c Low magnification
histology (H&E) of large PB invading the cerebellum in a WAP-Cre:Rbflox/flox:p53flox/flox mouse. Scale bar, 200 µm. CB, cerebellum; CC, cerebral cortex.
d High magnification H&E image of PB from a WAP-Cre:Rbflox/flox:p53flox/flox mouse, showing densely packed tumor cells with irregular nuclear shape
(inlet), scant cytoplasm, and rosette-like features (circled). Scale bar, 2 µm. Inlet, high power magnification (×100). e Left, PCR analysis of wild-type
control, flox control and two tumor samples, confirming deletion of Rb and p53 in PBs. Right, immunoblots of Rb/p53-deleted PBs and control cell lines for
pRb and p53. fMRIs of a WAP-Cre:Rbflox/flox:p53flox/flox mouse at indicated time points, showing gradual increase in PB size (red circles). g Dorsal images
of bright field (top) and fluorescent (bottom) microscopy of control wild-type mouse (left) and PB bearing WAP-Cre:Rbflox/flox:p53flox/flox:mT/mG mice
(right). Red, normal cells; green, tumor cells. h. Representative fluorescent and H&E images of a micro-tumor (arrows) in the pineal gland of WAP-Cre:
Rbflox/flox:p53flox/flox:mT/mG mouse. Right, widespread expression of ki67 in the micro-lesion. Scale bar, 200 µm. i Marker analysis of PB by IHC.
Synaptophysin is widely expressed; GFAP, PanCK and EMA are negative. Scale bars, 2 µm. j, k Representative IHC images showing strong expression of
ki67 but negative expression of p53 in Rb/p53-deleted PB. Scale bar, 2 µm. l Representative fluorescent, bright field, H&E, and IHC images showing large
metastases (arrows) on the leptomeningeal surface of the spine of WAP-Cre:Rbflox/flox:p53flox/flox:mT/mG mice. Top, original magnifications: left, ×10;
right ×25. Bottom, scale bars, 2 µm. Raw data are provided in Source Data files.
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average, NOR treatment suppressed tumor growth 7.03-fold
compared to control mice (Fig. 4e, f).
NOR acts as a CAD to inhibit autophagy. Tricyclic anti-
depressants have been shown to eliminate breast cancer cells by
interfering with serotonin transport37, and GBM cells by promoting
autophagy38. While tricyclic antidepressants inhibit serotonin and
norepinephrine re-uptake transporters and act as antidepressants,
they can also function as cationic amphiphilic drugs (CADs) that
interfere with lysosomal function39,40. To determine the mechanism
by which NOR exerts its inhibitory effect in PB, we first determined
whether it acts as serotonin-norepinephrine reuptake inhibitor
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(SNRI) or as CAD. To this end, we analyzed NOR side-by-side with
venlafaxine, an antidepressant drug that acts as SNRI but does not
have CAD properties, and with astemizole, an anti-histamine drug
that has CAD structure but no SNRI activity. Like NOR, astemizole
(CAD) effectively suppressed mouse PB cell growth whereas ven-
lafaxine (SNRI) did not (Fig. 5a), suggesting that NOR exerts its
effect through its cationic amphiphilic activity.
We next sought to determine whether NOR promoted autophagy
as was previously suggested for the effect of imipramine on
gliomas38. Imipramine, which ranked at the top 100–300 of 1288
drugs, depending on the parameters in our connectivity map
analysis, suppressed growth of primary PB cells, albeit much less
effectively than NOR (Supplementary Fig. 6a). As markers for
autophagy, we used two factors that execute autophagy and are
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themselves degraded by this process: the ubiquitin-binding protein
p62-sequestosome 1/SQSTM1, which targets proteins for selective
autophagy; and microtubule-associated proteins 1 A/1B light chain
3B/LC3B, involved in autophagosome biogenesis41. Western blot
analysis revealed accumulation of both proteins following 24-h
NOR treatment (Fig. 5b; Supplementary Fig. 6b). p62 level
remained high 48-h post-treatment (Supplementary Fig. 6b),
suggesting autophagy blockade. Immunofluorescent staining
demonstrated strong and sustained induction and colocalization
of p62 with LC3B (Fig. 5c; Supplementary Fig. 6c). Lamp-1
(lysosome-associated membrane protein 1), a lysosome membrane
specific marker, did not show robust induction following NOR
treatment but was colocalized with LC3b and p62 (Fig. 5c),
suggesting increased level of autolysosome formation.
To further investigate the effect of NOR on autophagic flux, we
used the tandem fluorescent-tagged LC3 reporter construct,
mRFP-GFP-LC3, and the differential stability of GFP and mRFP
fluorescent proteins at different pH42. During autophagy,
autophagosomes with their engulfed cargo fuse to lysosomes to
form autolysosomes where their cargo is degraded43,44. The
lysosomes and autolysosomes are highly acidic providing optimal
conditions for lysosomal hydrolases such as cathepsin proteases.
Whereas mRFP-LC3 is stable both in autophagosomes and
autolysosomes, GFP-LC3 is inactive under acidic conditions and
thus fluoresces only in autophagosomes. Thus, in cells expressing
mRFP-GFP-LC3, autophagosomes are labeled yellow (both GFP
and mRFP), whereas autolysosomes are red (mRFP). Primary Rb/
p53-deleted PB cells were transfected with mRFP-GFP-LC3 and
treated with the autophagy inhibitor chloroquine (CQ), autop-
hagy inducer rapamycin (RAP), vehicle control or NOR for 2 or
6 h. We observed increased percentage of yellow puncta in NOR
treated cells for both time points (Fig. 5d; Supplementary Fig. 7),
indicating blockade of autophagic flux at the autophagosome
stage or, as shown below, at the autolysosome stage due to
reduced acidity and impaired function.
CQ inhibits autophagy by deacidifying the lysosomes and
inhibiting its fusion to autophagosomes45. To determine whether
NOR can synergize with CQ, Rb/p53-deleted PB cells were treated
with vehicle alone, low CQ concentration (20 µM), or increasing
doses of NOR either alone or together with CQ for 24 h followed
by MTT assays to quantify cell viability. Synergy was calculated
using CompuSyn analysis [http://www.combosyn.com]46, with
combination index (CI) of <0.85 denoting synergy, CI= 0.9–1.0
additive, and CI > 1.1 antagonistic effects. Within the linear range
of inhibition by NOR alone, NOR plus CQ showed strong
synergy in suppressing growth of Rb/p53-deleted PB cells,
suggesting that these drugs suppress autophagy and/or cell
survival by different, yet complementary mechanisms (Fig. 5e;
Supplementary Fig. 6d).
NOR disrupts the lysosome, impeding autolysosome function.
The aforementioned results suggested that rather than inducing
autophagy, NOR suppresses this process by acting as a CAD.
CADs were previously shown to increase lysosomal membrane
permeability (LMP)47, and could thereby, like CQ, inhibit the
autophagic flux by disrupting the lysosome. To test for such an
effect in PB, we monitored the rate of lysosomal release of acri-
dine orange in response to NOR. Exogenously added acridine
orange enters lysosomes where it gets protonated, leading to a
shift in its emission spectrum from green to red; it further sen-
sitizes lysosomal membrane to photo-oxidation by blue light39.
When LMP is induced by photo-oxidation, acridine orange leaks
into the cytosol, causing loss of punctate red signal and increase
in diffused cytoplasmic green signal. To determine whether NOR
increases LMP, Rb/p53-deleted PB cells were treated with NOR or
vehicle control for 2 h, acridine orange dye was added and the
cells were subjected to photo-oxidation. Time-lapse microscopy
revealed a significant increase in the rate of green fluorescent
intensity, i.e., acridine orange release from lysosomes, in NOR
treated cells compared to control (Fig. 6a), indicating LMP
induction by NOR.
Lysosomal pH dictates the position of lysosomes within the cell;
peripheral lysosomes are less acidic than juxtanuclear lysosomes48.
LMP reduces acidity of lysosomes and shifts them to the periphery.
To determine the effect of NOR on lysosome localization, Rb/p53-
deleted PB cells were treated with NOR for 2 h, acridine orange was
added and the cellular localization of lysosomes was examined
under confocal microscopy. NOR treatment significantly increased
the fraction of peripheral lysosomes from 41 to 60% (Fig. 6b). LMP
also affects lysosomal volume and vice versa49. To determined
whether NOR affects lysosomal size, PB cells were treated with
increasing concentrations of NOR for 2 h and localization of
cathepsin B and Lamp-1 was assessed by immunofluorescent (IF)
staining. Lysosomal volume increased dramatically in proportion to
NOR concentration (Fig. 6c). To track lysosomes and cathepsin B
activity in live cells, we employed LysoTracker Green (LTG) and
Magic Red Cathepsin B, respectively. Increased NOR concentration
diminished the punctate green signal intensity of lysosomes, and
increased cathepsin B activity in the cytosol, which stained yellow,
indicating overlap of the two fluorescent dyes (Fig. 6d). In addition,
cell fractionation analysis demonstrated NOR treatment increased
levels of cathepsin B in the cytosol, while total cellular level of this
protease remained unchanged (Fig. 6e; Supplementary Fig. 8a).
Fig. 4 Nortriptyline predicted as a potential therapeutic for pineoblastoma. a Connectivity mapping by GWC of mouse Rb/p53-deleted PB identifies
multiple tricyclic drugs (red arrows) with nortriptyline (NOR) topping the list. These drugs including NOR ranked high in similar analysis with Rb/p53-
mutated PB, and using connectivity mapping by GSEA (Supplementary Tables 2 and 3). Color scale bar represents top 30 drugs when analyzing 100 genes
per signature. b Bright field (BF) image and synaptophysin expression in primary Rb/p53-deleted PB cells cultured as monolayer cells. Original
magnification, ×400. Flank tumors, developed following sub. cu. transplantation of primary Rb/p53-deleted PB into NOD/SCID mice, exhibit similar
histology (H&E staining) and synaptophysin expression as primary lesions. Scale bars, 2 µm. c Response of human HaCaT cells, Group 3 medulloblastoma
D425wt cells and three primary mouse Rb/p53-deleted PB cells (PB-1638, PB-1979, and PB-2804) to increasing concentrations of NOR, 24-h post
treatment using MTT assays. n= 3 for each group. One-way ANOVA, *P < 0.05, **P < 0.01. d Left, marginal caspase3/7 activity in mouse Rb/p53 PB-1638
and PB-2804 cells in response to increasing concentrations of NOR treatment for 1–2 h. Right, gemcitabine, used as a positive control, induces robust
caspase3/7 activity. n= 3 for PB-1638-1 h, PB-1638-2 h, PB-2804-1 h, PB-2804-2 h. Low caspase3/7 activity after 24-h NOR treatment is shown in
Supplementary Fig. 5a. e Left, representative MRIs of WAP-Cre:Rbflox/flox:p53flox/flox mice treated with vehicle control (n= 14) or NOR (n= 10; 20mg/
kg/day, i.p. with gradual increase to 40mg/kg/day), 5 days/week for 5 weeks. Right, fold tumor volume change compared to initial tumor volume. Two-
tailed unpaired student’s t-test, P < 0.002. PBs are indicated by red circles. f Histology of residual PB following treatment with NOR vs vehicle control
in vivo. Original magnification, ×400. Results in (c), (d) and (e) are representative of three independent experiments. Results are presented as mean ± SD
in (c), (d), and (e). For raw data see Source Data files.
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Finally, TEM revealed NOR induced accumulation of large
autophagic vacuoles containing partially degraded contents, lipid
droplets and laminar bodies, indicative of defective autolysosomes
(Fig. 6f; Supplementary Fig. 8b). Taken together, these results
suggest that NOR induces LMP, leading to proton and cathepsin
B release, and accumulation of enlarged, non-functional auto-
lysosomes, leading primarily to non-apoptotic cell death.
NOR synergizes with gemcitabine to suppress PB. Given the
similarity between PB and group 3 MB, and the sensitivity of
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the latter to pemetrexed and gemcitabine (GEM)50, we analyzed
the effects of these antineoplastic drugs on Rb/p53-deficient PBs.
We also analyzed inhibitors of Skp2 (SMIP004 and Skp2 III),
which effectively prevents spontaneous tumorigenesis in Rb+/−
mice51; cisplatin, currently used to treat PB, GBM, PNETs and
ependymomas; doxorubicin; and the PI3K/mTOR inhibitor
BEZ235. Gemcitabine had the lowest IC50 value (31.3 nM;
Fig. 7a), and was equally effective against Rb/p53-deleted and Rb/
p53-mutated PBs in vitro (Supplementary Fig. 9a). To determine
whether gemcitabine is effective against PB in vivo, 70–80-day-
old WAP-Cre:Rbflox/flox:p53flox/flox mice were treated with 60 mg/
kg GEM (i.v. injection, once a week for 5 weeks) and MRI was
performed on all mice at starting and end points. GEM sig-
nificantly suppressed PB growth 5.18-folds over this period
(Fig. 7b).
Inhibition of autophagy potentiates the effect of anti-neoplastic
cytotoxic drugs52,53. Indeed, NOR strongly synergized with GEM
in eliminating Rb/p53-deleted PB cells as well as human group 3
MB cells in vitro (Fig. 7c; Supplementary Fig. 9b). Annexin V/PI
flow cytometric analysis revealed that NOR plus GEM cooperated
to induce necrotic or late apoptotic, Annexin V+/PI+, cell death
after 24 h of treatment (Supplementary Fig. 9c). To investigate the
effect of NOR plus GEM combination therapy on PB in vivo,
weaned, 30 day old WAP-Cre:Rbflox/flox:p53flox/flox mice were
injected with vehicle alone, NOR (20 mg/kg/d, i.p.), GEM (60 mg/
kg/week, i.v.) or both drugs for 40 days. MRI analysis revealed a
significant inhibition in all treatment arms compared with sham
control (Fig. 7d). NOR plus GEM treatments had the most
significant effect, reducing tumor volume 4.26-fold compared to
control (P= 0.0004).
To corroborate these results with longer and continuous
follow-up, primary Rb/p53-deleted PB cells were subcutaneously
injected into NOD/SCID mice and, when tumor became palpable,
mice were treated with vehicle, NOR (10 mg/kg/d, i.p.), GEM
(60 mg/kg/week, i.v.) or NOR plus GEM. To assess for toxicity,
mouse weight was monitored throughout the course of treatment.
Although there was a trend toward reduced body weight, none of
these treatments had deleterious side effects (Supplementary
Fig. 9d). NOR plus GEM treatment significantly reduced tumor
growth (Supplementary Fig. 9d), and extended median survival
3.29-fold relative to control, 2.14-fold relative to GEM, and 2.14-
fold relative to NOR (Fig. 7e). Thus, NOR and GEM effectively
cooperate to suppress PB growth in preclinical models.
Modeling DICER1-deficient PB. In addition to RB1 loss, germ-
line mutation in DICER1, a ribonuclease involved in microRNA
processing and DNA repair, also predisposes children to PB6–8.
Using WAP-Cre, we deleted a floxed allele of Dicer1, flanking the
second RNasIII domain54, either alone or together with p53. Six
of nineteen WAP-Cre:Dicer1flox/flox:p53flox/flox mice (31.6%)
developed PB with incomplete penetrance by 270 days of age as
endpoint (Fig. 8a). For those mice that developed PB, the median
latency was 151.5 days. WAP-Cre:Dicer1flox/+:p53flox/flox mice
(n= 16) did not develop such lesions, indicating that both alleles
of Dicer1 must be disrupted to promote PB. WAP-Cre:Dicer1flox/
flox and WAP-Cre:Dicer1flox/+ mice with wildtye p53 also did not
develop PB.
Although the latency of WAP-Cre:Dicer1flox/flox:p53flox/flox
mice was significantly longer than that of WAP-Cre:Rbflox/flox:
p53flox/flox mice (P < 0.0001), they developed full blown PB with
characteristic pleomorphic nuclei, scarce cytoplasm and rosette
structures (Fig. 8b). Despite their substantial size, most Dicer1/
p53-deficient PBs did not protrude the brain as did Rb/p53-
deleted lesions.
We also generated WAP-Cre:Dicer1flox/flox:Rbflox/flox:p53flox/flox
mutant mice with deletion of all three tumor suppressors. These
mice developed bulging PB that initiated earlier than Rb/p53-
deficient tumors but showed reduced penetrance (13 of 14 mice;
92.9%) by 270 days of age, and wider latency (median latency
138 days), yet with similar histology as Rb/p53 and Dicer1/p53
lesions (Fig. 8a–b). Deletion of Dicer1 and p53 but not Rb in
WAP-Cre:Dicer1flox/flox:p53flox/flox mice, and deletion of all three
genes in WAP-Cre:Dicer1flox/flox:Rbflox/flox:p53flox/flox mice were
confirmed by PCR (Fig. 8c).
To molecularly assess Rb pathway loss in these PBs, we
performed pathway activity analysis using an RB knockout
signature55. As expected, Rb/p53- and Rb/Dicer1/p53-deletion
PBs exhibited high RB pathway loss compared to control brain
tissue (Fig. 8d). In contrast, only one Dicer1/p53 PB exhibited
similar increase in RB loss signaling, whereas the other two
tumors showed elevated but not robust RB loss activity. E2F1-3
pathway activation analysis55 revealed elevated signaling in one
or more of these transcription factors downstream of RB-loss in
each Dicer1/p53 lesion. There was very high activity of E2F2 in
the single PB with robust RB loss signaling, which may reflect an
oncogenic induction in this particular tumor.
GSEA-PC analysis revealed that Dicer1/p53 and Rb/Dicer1/
p53 PBs clustered closely with Rb/p53-deficient PBs and mouse
RB as well as with human PB, but away from GMB (Fig. 2a,
Supplementary Fig. 3). Thus, the WAP-Cre transgene can be used
to model germline mutations in PB, and combined deletion of
Rb-p53 o rDicer1-p53 via this deleter line induces histologically
similar PBs with distinct kinetics as observed in children10.
General sensitivity of PB to NOR. To identify potential ther-
apeutic targets for Dicer1-defcient PB, we performed CMAP
analysis on the Dicer1-mutant PBs as described in Fig. 4a for Rb/
p53-deficient lesions. NOR and other tricyclic/anti-psychotic
medicine (chlorpromazine, clomipramine, fluphenazine and
norcyclobenzaprine) appeared again among the top predicted
drugs for both Dicer1/p53 and, to a lesser extent, Rb/Dicer1/p53
Fig. 5 Nortriptyline impairs autophagy in pineoblastoma cells. a MTT assays of mouse Rb/p53 deficient PB cells treated for 24 h with vehicle control or
increasing concentrations of venlafaxine, nortriptyline (NOR) or astemizole (chemical structures on the right). n= 3 for each group. One-way ANOVA,
****P < 0.0001, n.s.= not significant. b Immunoblots of mouse PB cells treated with vehicle control or increasing concentrations of NOR for 24 h, showing
elevated p62 and LC3B but not Lamp-1 expression. c Top, mouse PB cells treated with vehicle control or increasing concentrations of NOR for 2 h and then
immunostained for LC3B (purple), p62 (green), and Lamp-1 (red). Bottom, fluorescent intensity quantified using ImageJ. Scale bar, 20 µm. One-way
ANOVA, *P < 0.05, ***P < 0.001, ****P < 0.0001, n.s.= not significant. d Top, assessment of autophagosome (AP, yellow) and autolysosome (AL, red)
puncta using mRFP-GFP-LC3 reporter plasmid transfected into mouse PB cells, followed by treatment with chloroquine (CQ, 20 µM), rapamycin (500 nM),
vehicle control or increasing concentrations of NOR for 2 h. Bottom, intensities of yellow and red puncta measured using ImageJ with JACoP plug-in. Scale
bar, 20 µm. Two-tailed student’s t-test, *P < 0.05, **P < 0.01. Additional cell lines and duration of treatments are shown in supplementary Fig. S7. e MTT
assays of mouse PB cells treated with vehicle control (n= 3), chloroquine (n= 3; 20 µM), increasing concentrations of NOR alone (n= 3), or together with
chloroquine (n= 3; 20 µM). Synergism was calculated using CompuSyn (CI < 0.85 denotes synergy). Results are presented as mean ± SD in (a), (c), (d),
and (e). See Source Data files for raw data.
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PBs (Fig. 8e; Supplementary Tables 4 and 5). The Oxidative
Phosphorylation (OXPHOS) inhibitor, antimycin A, was also
predicted to suppress PBs from all three models. Rb/Dicer1/p53-
deficient, but not Dicer1/p53-deficient, primary PB cells could
readily be cultured in vitro and they exhibited high sensitive to
NOR (Fig. 8f).
Finally, very few human PB cell lines have been successfully
established in culture. One line, TS13-19, isolated from sporadic
PB and propagated as non-adherent tumorspheres in serum-free
media56, was also highly sensitive to NOR (Fig. 8g). Together,
these results demonstrate that mouse and human PBs with
different oncogenic drivers exhibit elevated sensitivity to NOR/
lysosome disruption, indicating the potential benefit of this drug
for diverse types of PB.
Discussion
We report the development of tractable immune-competent
mouse models for the two major germline mutations that drive
PB in children, RB1 and DICER1. We employed a WAP-Cre
deleter line, commonly used to target mammary lobular-alveola
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during estrous cycle and pregnancy13. The initial publication on
this transgene demonstrated low expression in whole brain tissue.
Our results now demonstrate that this transgene is expressed in
the developing pineal gland and, to a lesser extent, in the pituitary
gland. This is likely due to erroneous expression of this transgene
at the specific integration site in this line as we observed only
marginal expression of endogenous WAP gene in the pineal
gland. PBs were observed following WAP-Cre-mediated deletion
of Rb plus p53 or Dicer1 plus p53, but not after deletion of any of
these genes alone or following combined disruption of Pten plus
p53, indicating a unique sensitivity of pineal gland cells to
combined disruption of Rb or Dicer1 plus p53.
Nonetheless, various WAP-Cre-based transgenic mice may
only induce benign lesions or have subtle effects on the pineal
gland. This gland plays a central role in coordinating circadian
rhythms by releasing melatonin. In turn, melatonin modulates
renewal of hematopoietic stem and progenitor cells57, controls
the circadian clock, and its perturbation has been implicated in
different types of cancer, including those of the breast58. These
considerations should be taken into account when using WAP-
Cre to study tumorigenesis of the mammary epithelium.
Consistent with the short median latency of RB1 versus
DICER1 PB subtypes in children10, WAP-Cre-mediated deletion
of Rb plus p53 had a shorter latency and 100% penetrance
compared with longer latency and incomplete penetrance of the
Dicer1/p53 model. The Dicer1 mouse used here deletes most of
the second RNasIII domain upon Cre-mediated deletion, yet the
deletion is in-frame, yielding a defective but stable protein54.
miRNA-independent roles of Dicer1 have been demonstrated
suggesting the truncated, RNasIII deleted, Dicer1 protein may
still be functional in microRNA-independent contexts that may
impact tumorigenesis59. It would therefore be important to
determine whether complete homozygous deletion of Dicer1
would increase the penetrance of PB.
To identify the cell of origin of these PBs, we have performed
lineage-specific marker analysis. In preliminary results, micro-
tumors from 30 day old Rb/p53-deleted mice as well as full-blown
tumors stained positive for 5-hydroxytryptamine receptor (5-HT,
serotonin receptor), which marks matured pinealocytes60, but
were completely negative for pax6 (pinealocyte precursor cells),
nestin (neuronal stem cells) and the microglia marker ox42. Thus,
combined deletion of Rb/p53 or Dicer1/p53 in pinealocytes may
induce partial dedifferentiation leading to reduced expression of
5-HT. Assignment of pinealocytes as the cells of origin is also
consistent with the ability of IRBP transgenic mice to induce PB,
albeit at low frequency, following Rb deletion or following over-
expression of cyclin D1, the latter of which induces pRb phos-
phorylation and inactivation, on p53 null background12,29.
Notably however, Cyclin D1 has other targets in addition to cell
cycle control61, and there is no evidence so far that this cyclin or
other D type cyclins are amplified in PB. It is also possible that
combined loss of Rb and p53 induces partial trans-differentiation
of another lineage into weakly 5-HT-expressing cells. Similar
considerations were made during the search for a cell of origin for
RB. Definite assignment involved systemic functional analysis of
various retinal precursors, showing that RB1 knockdown in post-
mitotic human cone precursors but not other progenitors induced
cell proliferation, leading to tumors with features of RB following
orthotopic transplantation62.
Our in silico drug prediction analysis identified multiple tri-
cyclic, antidepressant drugs such as NOR, which ranked at the
top, as potential therapeutics for Rb/p53-deleted and Rb/p53-
mutated PBs as well as for Dicer/p53- and Rb/Dicer1/p53-defi-
cient lesions. NOR inhibited growth of primary Rb/p53- and Rb/
Dicer1/p53-deficient PB cells as well as a human PB cell line56.
NOR suppressed autophagy flux not by blocking assembly of the
autolysosome but by disrupting the lysosome. Lysosome disrup-
tion caused cathepsin release and reduced acidity, leading to
accumulation of large, non-functional autolysosomes and largely
non-apoptotic cell death. NOR induced accumulation of lyso-
somes, cathepsin B activity and expression of the pro-autophagy
factors LC3B and p62, likely as a result of an auto-regulatory
feedback response to defective lysosomes and reduced autophagic
flux (Fig. 9). Lysosome disruption may be superior to autophagy
inhibitors as it induces additional lethal effects such as cathepsin-
release63.
NOR is given as anti-depressant at maximal dose of 150 mg/
day, which is, for an average 75 kg person= ~2 mg/kg. Small
animals metabolize drugs faster than large animals, and mouse
doses can be as high as 12.3 times more than humans64. This
translates into NOR dose of 2 mg/kg × 12.3= 24.6 mg/kg for
mice. For NOR treatment alone, we started with 20 mg/kg and
slowly increased the dose to 40 mg/kg, whereas in combination
with GEM, we kept the dose at 20 mg/kg (mouse models) or 10
mg/kg (flank assays). Thus, NOR doses used here for mice are
directly applicable to humans. Of note, meta-analysis of tricyclic
antidepressant users found a significant reduction in incidence of
glioma and colorectal cancer65. Moreover, for lung cancer, tri-
cyclic antidepressants or antihistamines significantly improved
survival40,66.
In conclusion, we developed new preclinical models for the
most prevalent germline mutations that drive PB; RB1 and
DICER1, as well as for combined RB1 plus DICER1 loss on p53
null or mutant background. These immune-competent models
should be instrumental in evaluating mechanism of dissemination,
identifying cell of origin and candidate new therapeutics targeting
Fig. 6 Nortriptyline disrupts the lysosome in pineoblastoma cells. a Acridine orange release assay in mouse PB cells treated with vehicle control (n= 3)
or 30 µM NOR for 2 h. Changes in green fluorescent intensity at different time points measured using ZEISS LSM 700 confocal microscope. Scale bar,
10 µm. Two-tailed paired student’s t-test, ****P < 0.0001. b Lysosome localization assay. Mouse PB cells were treated with vehicle control or NOR
(12.5 µM for 2 h). Acridine orange was added and location of lysosomes relative to nuclei determined. Scale bar, 20 µm. Chi-Square test, P= 0.0072.
c Representative IF analysis for lysosomal membrane permeability using cathepsin B (green) and Lamp-1 (red) antibodies in PB cells treated with vehicle
control or 30 µM NOR. Inlets, normal (top) vs enlarged (bottom) images of lysosomes (yellow arrows). Scale bar, 20 µm. d Lysosome integrity and
cathepsin B activity assays. PB cells treated with vehicle control or increasing concentrations of NOR for 2 h were analyzed by LysoTracker and Cathepsin B
Magic Red Kit under ZEISS LSM700 confocal microscope. Scale bar, 10 µm. e Top, Western blot analysis of cathepsin B expression in cytoplasmic fractions
(Cyto.) in PB 2804 cells treated with increasing concentration of NOR for 2 h. Bottom, total cathepsin B levels in whole cell lysates remained relatively
unchanged. f Representative TEM images of PB cells treated with vehicle control (n= 6) or 30 µM NOR (n= 16) for 2 h showing increased number of
autophagic vacuoles compared to control cells (top left and top right). Autophagic vacuoles (red arrow) are filled with lipid droplets (blue arrow), partially
degraded contents (brown arrow) and lamellar bodies (green arrow; bottom right). Scale bars, 5 µm (top panel) and 1 µm (bottom panel). Bar graph
comparing the number of large autophagic vacuoles per cell by TEM, using 6 control and 16 NOR treated cells. Two-tailed t-test, P < 0.0001. Results are
presented as mean ± SD in (a) and (f). See Source Data files for raw data.
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the immune system and both primary and metastases. We showed
that diverse mouse and human PB cells are highly sensitivity to the
FDA-approved tricyclic antidepressant NOR, which disrupts the
lysosome, leading to inhibition of autolysosome function, cathe-
psin release, and cell death. Lastly, we demonstrated that NOR
synergizes with gemcitabine to effectively suppress PBs in our
preclinical model, suggesting a new therapeutic approach for this
rare, yet lethal pediatric cancer.
Methods
Generation of Rb-deficient and Dicer1-deficient mouse model. All mouse
experiments were performed in accordance with the current Canadian Animal
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Care Council guide for the care and use of laboratory animals and were approved
by the Toronto General Research Institute Animal Research Committee, UHN. To
generate experimental and control mice, WAP-Cre:Rbflox/flox mice and p53flox/flox
or p53LSLR270H/+ mice were bred to obtain WAP-Cre:Rbflox/+:p53flox/+ and WAP-
Cre:Rbflox/+:p53LSLR270H/+ mice, respectively. Subsequently, WAP-Cre:Rbflox/+:
p53flox/+ mice were interbred to generate WAP-Cre:Rbflox/flox mice, WAP-Cre:
p53flox/flox mice and WAP-Cre:Rbflox/flox:p53flox/flox mice. WAP-Cre:Rbflox/+:
p53LSLR270H/+ mice and WAP-Cre:Rbflox/+:p53flox/+ mice were bred to generate
WAP-Cre:Rbflox/flox:p53LSLR270H/+ and WAP-Cre:Rbflox/flox:p53LSLR270H/f mice.
Control and experimental mice were on mixed genetic backgrounds. Mouse gen-
otyping was performed as previously described14. The mT/mG, a double fluor-
escent Cre reporter mouse, generously provided by Dr. Hitoshi Okada, was crossed
with WAP-Cre:Rbflox/flox:p53flox/flox mice to generate WAP-Cre:Rbflox/+:p53flox/+:
mT/mG mice. Subsequently, WAP-Cre:Rbflox/+:p53flox/+:mT/mG mice were
interbred to generate WAP-Cre: Rbflox/flox:p53flox/flox:mT/mG mice. Dicer1-floxed
mice (#006366) obtained from the Jackson Laboratory were bred to generate WAP-
Cre:Dicer1flox/flox, WAP-Cre:Dicer1flox/flox:p53flox/flox, WAP-Cre:Dicer1flox/flox:
p53flox/flox:mT/mG and WAP-Cre:Dicer1flox/flox:Rbflox/flox:p53flox/flox mice.
Cell culture and drug treatments. Primary tumor cell lines were established from
WAP-Cre:Rbflox/flox:p53flox/flox, WAP-Cre:Rbflox/flox:p53LSL_R270H/flox and WAP-
Cre:Dicer1flox/flox:Rbflox/flox:p53flox/flox mice as described below. PB lesions were
surgically removed, dissociated into single cells using accutase (Thermo Fisher
Scientific, #A1110501), passed through 40 µm cell strainer (BioShop, #SP104151),
and plated on laminin-coated Primaria plate (VWR, #47743-734; Fisher scientific,
#08-772-4 G). D425wt is a human Group 3 MB cell line (MDT). TS13-19 is a
human PB cell line56, All cell lines were cultured in Neurobasal medium (Gibco,
#LS21103049) supplemented with 2mM L-Glutamine (Gibco, #25030081), 1X B27
(Gibco, #154044), 10 ng/ml rhEGF (Gibco, #PHG0311L), 10 ng/ml bFGF (Gibco,
#PHG0266), 75 µg/ml BSA (BioShop, #ALB001.50), 2 µg/ml heparin (BioShop,
#HPA333.100) and 1X Penicillin-Streptomycin (Gibco, #15140122).
For MTT assay, the following drugs were used: NOR (Sigma, #N7261),
astemizole (Sigma, A2861), venlafaxine (Selleckchem, #S1441), imipramine (Sigma,
#I0899), chloroquine (BioShop, #CHL919), rapamycin (BioShop, #RAP004), Skp2
SMIP004 (EMD Millipore, #500517), Skp2 III (EMD Millipore, #506305), cisplatin
(Selleckchem, #S1149), NVP-BEZ235 (Selleckchem, #S1009), pemetrexed
(Selleckchem, #S1135), and gemcitabine (Selleckchem, #S1149).
1 × 104 primary tumor cells were plated on 96-well Primaria plate coated with
laminin. After 24 h, cells were treated with vehicle control or drugs of interest for
24 h. After treatment, MTT solution was added, incubated for 3 h, solutions were
aspirated, 100 µl DMSO was added and OD570 readings were taken with Vmax
Kinetic Microplate Reader. Synergy was calculated using CompuSyn software,
where combination index (CI) of <0.85 was considered as synergistic, CI= 0.9–1.0
as additive, and CI > 1.1 as antagonistic.
For confocal and two-photon microscopy, cells were plated on Nunc Lab-Tek II
Chamber slide (Sigma, #C7057) coated with laminin.
mRFP-GFP-LC3 reporter assay. Primary tumor cells were transfected with
mRFP-GFP-LC3 using TurboFect Transfection Reagent (ThermoFisher, #R0531).
After transfection, cells were treated with chloroquine (20 µM), rapamycin
(500 nM), vehicle control or increasing concentrations of NOR. Intensities of
yellow and red puncta were measured using ImageJ with JACoP plug-in.
Gross histological analysis. Brains and spinal cords were dissected from normal
and tumor-bearing mice carrying mT/mG reporter. Tissues were fixed in 10%
formalin for >24 h. Gross anatomy and fluorescence signals were examined using
the CRI Maestro system.
Histopathological, IHC/IF, and immunoblot analysis. Mouse brains were dis-
sected along with skull, fixed in 10% formalin, decalcified in 0.5 M EDTA, and
incubated in 30% sucrose solution. The brain and skull were cut into 250 µm
sections using Leica SM2000R sliding microtome, and sections were viewed under
ZEISS LSM710 two-photon microscope to locate micro-lesions. For H&E staining,
tissues were cut as 5 µm sections. The following primary antibodies were used to
conduct IHC and IF staining: p53 (1:100, Santa Cruz, C, #SC-126), synaptophysin
(1:200, Cell Signaling, #36406), cathepsin B (1:800, Cell Signaling, #31718), GFAP
(1:100, Cell Signaling, #3670), Lamp-1 (5 µg/ml, DSHB, 1D4B), LC3B (1:200, Cell
Signaling, #3868), nestin (1:100, Abcam, #ab11306), ki67 (1:200, Biocare Medical,
#CRM325), neurofilament (5 µg/ml, DSHB, #2H3), OX42 (5 µg/ml, DSHB, #M1),
PAX6 (5 µg/ml, DSHB, #PAX6), p62 (1:100, Abnova, #H00008878-M01), pit1 and
5-HT (1:1000, ImmunoStar, #20080). Secondary antibodies used for immunohis-
tochemistry and immunofluorescence staining: Alexa Fluor 488 anti-mouse (1:200,
Life Technology, #Z25002), Alexa Fluor 488 anti-rabbit (1:200, Life Technology,
#Z25302), Cy5 anti-rat (1:200; Life Technology, #A10525), Alexa Fluor 568 anti-
mouse (1:200, Life Technology, #Z25006), Alexa Fluor 568 anti-rabbit (1:200, Life
Technology, #Z25306), Biotinylated Goat Anti-Rabbit (1:200, Vector Laboratories,
#BA-1000), Biotinylated Horse Anti-Mouse (1:200, Vector Laboratories, BA-2000).
To determine subcellular localization of cathepsin B after NOR treatment,
lysates from cytosolic compartment were extracted. Briefly, after vehicle control or
NOR treatment, cells were collected by centrifugation and resuspended in cytosolic
buffer (20 mM/L HEPES, 10 mM/L KCl, 1.5 mM/L MgCl2, 1 mM/L EDTA,
250 mM/L sucrose, 1.5 mM/L PMSF, 1 mM/L DTT, protease inhibitor cocktail
(Sigma, P8340)). The cells were lysed on ice by passing through 26 G syringe 30
times, centrifuged for 30 min at 4 ˚C and 13,200 rpm. The supernatant was
centrifuged once again for 30 min. Protein concentration was measured using
NanoDrop 2000 (ThermoFisher) and resolved by SDS-PAGE.
The following primary antibodies were used to conduct immunoblotting: Rb,
p53, α/β-tubulin (1:1000, Cell Signaling, #2148), Lamp-1 (0.5 µg/ml, DSHB, 1D4B),
p62 (1:1000, Abnova, # H00008878-M01), LC3B (1:1000, Cell Signaling, #3868),
actin (0.5 µg/ml, DSHB, JLA20), and cathepsin B (1:1000, Cell Signaling, #31718).
Secondary antibodies were: HRP-linked Anti-rabbit IgG (1:1000, Cell Signaling,
#7074S), HRP-linked Anti-mouse IgG (1:1000, Cell Signaling, #7076 S) and HRP-
linked Anti-rat IgG (1:1000, Cell Signaling, #7077S).
Transmission electron microscopy (TEM). Primary tumor cells were treated with
vehicle control or 20 µM NOR for 2 h, fixed in 2% glutaraldehyde in 0.1 M sodium
cacodylate buffer (pH= 7.3) overnight. Then, cells were rinsed, post-fixed, dehy-
drated and infiltrated according to the procedure at The Nanoscale Biomedical
Imaging Facility at The Hospital for Sick Children Research Institute, Canada. Thin
sections were obtained using Leica Ultracut Ultramicrotomes and analyzed with
FEI Tecnai 20 TEM.
MRI imaging and in vivo therapeutic analysis. Mice treated with indicated
regimens were injected with gadolinium by i.v. to enhance contrast prior to MRI.
Tumor volumes were calculated using Medical Image Processing, Analysis &
Visualization (MIPAV) software [https://mipav.cit.nih.gov]67.
Primary tumor cells (2 × 106) were suspended in 20 µl neurobasal media mixed
1:1 with 20 µl Matrigel and transplanted subcutaneously into the right flank of
NOD/SCID mouse. Once tumors were palpable, mice were randomized and treated
until end-point (tumor volume= 550 mm3). Tumor volume was calculated using
V= π/6 x L xW xH. Mice were treated with vehicle control, 10 mg/kg NOR, 60
mg/kg gemcitabine or a combination of both. NOR was injected i.p. 4 days a week;
gemcitabine was injected i.v. once a week.
Apoptosis assays. Rb/p53-deleted PB cells (1.5 × 104) were seeded in 96-well
plates and treated with indicated drugs and durations. Caspase 3/7 activity was
measured as per manufacturer’s instructions (Promega Caspase-Glo 3/7 Assay
System; #G8090).
For flow cytometry analysis, cells (7.5 × 104) were seeded onto 24-well plates
and treated with indicated drugs. 24-h post treatment, the cells were stained with PI
and Annexin V (BD FITC Annexin V Apoptosis Detection Kit I; #556547) and
analyzed using BD LSR Fortessa cell analyzer. FSC-A vs SSC-A plots were used to
Fig. 7 Nortriptyline synergises with gemcitabine to suppress pineoblastoma. a IC50 values (in nM) following MTT assays of mouse Rb/p53 PB cells
treated with indicated drugs. Gemcitabine was most potent (IC50= 31 nM). b Left, representative MRIs of WAP-Cre:Rbflox/flox:p53flox/flox mice treated
with vehicle control (n= 14) or gemcitabine (n= 8; 60mg/kg/week, i.v.) for 5 weeks. Right, fold tumor volume change compared to initial tumor volume.
These experiments were performed side-by side with those described in Fig. 4e, and the control arm is the same. Two-tailed unpaired Student’s t-test, P <
0.003. PBs are indicated by red circles. c MTT assays of mouse PB cells treated with vehicle control (n= 3), gemcitabine alone (n= 3), increasing
concentrations of NOR alone (n= 3) or co-treatment with gemcitabine (n= 3; 20 nM or 40 nM). Cooperation Index was calculated using CompuSyn (CI <
0.85 indicates synergy). d Representative MRIs of WAP-Cre:Rbflox/flox:p53flox/flox mice treated with vehicle control (n= 3), gemcitabine (n= 3; 60mg/
kg/week, i.v.), NOR (n= 4; 20mg/kg/day, i.p.), or both drugs (n= 6). Treatments commenced at 30 days of age and MRIs were taken 40 days later.
Statistical analysis by two-tailed unpaired student’s t-test. PBs are indicated by red dashed circles. e Kaplan–Meier survival curve of NOD/SCID mice
following sub. cu. injections of primary PB cells, treated with control, gemcitabine (60mg/kg/week, i.v.), NOR (10mg/kg/d, i.p.) or both drugs. Endpoint
was set as tumor volume > 550mm3. Statistical analysis by Mantel-Cox test. Results in (c) are representative of three independent experiments. Results
are presented as mean ± SD in (b), (c), and (d). See Source Data files for raw data.
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gate cells, excluding debris, as per the BD manual. Annexin V FITC vs propidium
iodide (PI) plots from the gated cells uncovered populations corresponding to
viable, apoptotic or necrotic cells.
Acridine orange assays. Primary PB cells were treated with vehicle or 30 µM
NOR for 2 h. Acridine orange (final concentration= 2 µg/ml) was added 20 min
before the end of treatment. Photo-oxidation was induced by exposing cells to blue
light, and changes in green intensity (eGFP) were captured using ZEISS LSM700
confocal microscope. To determine lysosome location, primary tumor cells were
treated with vehicle control or 12.5 µM NOR for 2 h. Acridine orange solution
was added as above and lysosomes and cytoplasm were captured with red
(mCherry) and green (eGFP) filters using ZEISS LSM700 confocal microscope,
respectively. Location of lysosomes relative to nucleus was assessed using ImageJ
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software. Lysosomes were considered as juxtanuclear when they were within
4 µM-range from the nucleus, and perinuclear when they were outside the 4 µM-
range.
Gene expression, pathway enrichment, and activity analyses. To compare Rb/
p53-deleted PBs and Rb/p53-mutated PBs, RNA was collected from snap-frozen
tumor tissues and analyzed on Mouse Gene 1.0 ST Array (Affymetrix).
Gene expression profiles of human SHH MB, group 3 MB, and PB were
analyzed using dataset from Mixed Pediatric PDX (public) – Olson – 55- MAS5.0 –
u133p2 [https://hgserver1.amc.nl/cgi-bin/r2/main.cgi]. Using “view multiple
genes”, the expression profiles of top 10 genes from human SHH and group 3 MB
were compared between human SHH MB, group 3 MB, and PB. Using “find
differential expression between groups”, differentially expressed genes between
human SHH MBs and PBs were identified. From these, 95 genes were used to
determine the expression profile in Rb/p53-deleted PBs.
Fig. 8 Dicer1 plus p53 deletion via WAP-Cre induces low-penetrant pineoblastoma. a Kaplan–Meier PB-free survival curves showing that WAP-Cre:
Dicer1flox/flox:p53flox/flox mice (n= 19, magenta) developed PB with 31.6% penetrance. Mantel-Cox test, p < 0.0001 vs Rb/p53-deficient PBs. WAP-Cre:
Dicer1flox/flox:Rbflox/flox:p53flox/flox triple mutant mice (n= 14) developed pineoblastoma with reduced latency of 138 days and 92.9% penetrance. P=
0.0003 vs Dicer1/p53 and P= 0.017 vs Rb/p53-deficient PBs. b Representative H&E images of whole brain and histology of PBs from indicated genotypes.
Inlets, high power magnification (×100) showing similar pleomorphic PBs. Scale bars, 200 µm (top), 2 µm (bottom). c PCR analysis confirming deletion of
Rb, Dicer1 or p53 alleles in indicated PBs. d RB KO signature and E2F1-3 pathway activity in Rb/p53, Dicer1/p53 and Rb/Dicer1/p53 PBs relative to normal
control brain. Scale bar represents pathway activity probability. For GSEA-PCA-based clustering of these lesions with human brain tumors, see Fig. 2a.
e Connectivity mapping by GWC of mouse Dicer1/p53-deficient (left) and Rb/Dicer1/p53-deficient (right) pineoblastomas identifies multiple tricyclic
drugs including NOR (red arrows). 1–4 refers to 100, 200, 300, and 500 genes per signature used for each analysis. Color scale bar represents top 30
drugs when analyzing 100 genes per signature. f Response of mouse Rb/Dicer1/p53-deficient pineoblastoma cells to increasing concentrations of NOR for
24 h using MTT assays. Results show values from three independent experiments each performed in triplicates. **** P < 0.0001. Statistical analysis by two-
tailed student’s t-test. g Response of human TS13-19 PB cells to increasing concentrations of NOR for 24 h by MTT assays, performed in triplicates; **P <
0.002. Results are represented as mean ± SD in (f) and (g). See Source Data files for raw data.
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Fig. 9 Model for the cytotoxic effect of nortriptyline on pineoblastoma. In untreated cells (left), autophagosomes with their cargo fuse to lysosomes,
which provide digestive enzymes such as cathepsins and high acidic environment (yellow) for their enzymatic activity, to form functional autolysosomes
where the cargo is degraded. Both mouse and human pineoblastomas are highly sensitive to the cationic amphiphilic (CAD) tricyclic drug nortriptyline,
which disrupts the lysosomes leading to release of protons and cathepsins, and to accumulation of non-functional autolysosomes that fail to degrade their
payload, ultimately leading to cell demise (right). Tumor cells utilize autophagy as an escape mechanism to evade anti-neoplastic cytotoxic drugs, and, in
accordance, nortriptyline effectively cooperates with gemcitabine to suppress pineoblastoma.
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GSEA was performed with v2 using PreRanked Method, a two-sided
calculation. The resulting enrichment scores (ES) were normalized by multiple
sample correction for normalized enrichment score (NES). Furthermore, the
multiple gene/sample correction was done with 1000 permutations to generate
FDR values. Specific values for metastatic pathways: WINNEPENNINCKX_
MELANOMA_METASTASIS_UP, Nominal p-value: <0.0001 FDR: 0.0302 ES:
0.3505 Normalized ES: 1.6770;
TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C, Nominal p-value: <0.0001
FDR: 0.0032 ES: 0.3660 Normalized ES: 1.9651; RICKMAN_METASTASIS_UP,
Nominal p-value: <0.0001 FDR: 0.0012 ES: 0.3946 Normalized ES: 2.0646
BIDUS_METASTASIS_UP, Nominal p-value: <0.0001 FDR: 0 ES: 0.4592
Normalized ES: 2.2868.
Dicer1-deficient tumors were analyzed using Mouse Gene 2.0 ST Array. For
comparative GSEA-PC and pathway activity analyses we used the specific probes in
each platform (1.0 ST and 2.0 ST). Pathway activity was calculated for RB KO
signature and E2F1, E2F2, and E2F3 pathways using binary regression models’
script Binreg v2.0 in the MatLab environment and related pathway training data set
as described68.
In silico drug prediction. Transcriptional profiles of drug-treated cancer cell lines
from the BROAD Connectivity map initiative (CMAP, n= 1309 drugs) were
obtained using the PharmacoGx package and a linear regression model as
described in R35. Pre-computed CMAP drug perturbation signatures for 1288
drugs were used in the downstream analysis. These signatures signify the drug
concentration effect on the transcriptional state of the cell, and were used to
identify genes whose expression is perturbed by drug treatment. Gene expression
‘signatures’ pertaining to each of the mouse models were obtained by comparing
samples of each model against normal tissue samples, to identify differentially
expressed genes using the limma package69. A linear model per gene was fit using
the lmfit function, followed by an empirical Bayes adjustment using the eBayes
function to generate several statistics for differential expression (t-stat, log-odds
ratio). Final annotations and multiple-testing correction (FDR) adjustments were
taken using the topTable function, and genes were considered based on a threshold
of FDR < 0.01.
Drug repurposing of CMAP against each signature was conducted on the
orthologous genes common between the mouse signatures and CMAP perturbation
signatures. Rb/p53 ‘signatures’ specific to each mouse model were chosen by
selecting equal numbers of significant up- and downregulated differentially
expressed genes. Several signature sizes were tested, spanning 100, 300, and 500
genes, respectively. Rb/p53 mouse model signatures were compared against drug
perturbation signatures from CMAP to identify drugs that could reverse the mouse
model signature (i.e., could be a potential therapeutic drug). Connectivity scores
between CMAP drug perturbation signatures and each of the mouse model
signatures were computed using the connectivityScore function of the PharmacoGx
package. Connectivity scores were computed using the GSEA method, based on the
Kolmogorov-Smirnov (KS) statistic, as well as the GWC method (based on the
weighted spearman statistic). Drugs were ranked by their connectivity score and
associated p-value, with more negative connectivity scores indicating the ability for
a given drug to reverse the mouse signature. Top hits were considered by filtering
drugs with connectivity scores below −0.5 for both GSEA-based and GWC-based
analyses. Similar conditions were used for CMAP analysis of mouse Dicer1/p53-
and Rb/Dicer1/p53-deficient PBs.
GSEA-PCA. Human and mouse gene expression profiles were collated from in-
house experiments, and datasets from the NCBI Gene Expression Omnibus (GEO)
including MB (GSE37382), GBM (GSE36245), and Rentioblastoma (GSE29685,
GSE24673, GSE59983). Gene expression profiles of each dataset were processed
separately within R (version 3.5.0) and Bioconductor, using the Geoquery and affy
packages and probe level information from BrainArray, as described22. Single-
sample Gene Set Enrichment Analysis (ssGSEA)70 was conducted on human and
mouse expression profiles using the GSVA package (version 1.32.0) in R. Resultant
gene sets were filtered to encompass only those genesets common to both mouse
and human datasets. Single-sample geneset ES across the genesets were then
combined to generate an ssGSEA-ranked matrix. Principal component analysis
(PCA) was then conducted on 578 ssGSEA-ranked genes sets (rank matrix).
Genome-wide connectivity scores (GWC method) were determined using a
weighted spearman correlation statistic. In supplementary Tables, significance of
the scores was determined by permutation testing (1000 permutations) and a two-
sided test. Connectivity scores generated using the GSEA method are based on KS
statistic implemented in the piano package. Returned p-values are distinct-
directional p-values adjusted following permutation sampling (1000 permutations).
Statistics and reproducibility. Data are presented as mean ± SD. All statistical
analyses listed in figure legends and Kaplan–Meier survival curves were generated
using GraphPad Prism. Quantification of fluorescent intensity was performed using
ImageJ software. With the exception of human PB TS13-19 cells, which were
analyzed once in triplicates as they were extremely difficult to propagate, all drug
studies were performed in three or more replicates each, in three biological
replicates.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Accession number: The NCBI Gene Expression Omnibus accession number for the
microarray results reported in this paper is GSE124537. GSE37382, GSE36245,
GSE29685, GSE24673 and GSE59983 are publicly available.
Source data: The source data underlying Figs. 1e; 3g; 4c–e; 5a–e; 6a–b, e, f; 7a–d, 8c,
f–g; and Supplementary Figs. 5a, 6a–b, d; 7; 8a, 9a–d; are provided as a Source Data file.
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